The plaintiff sought leave under Part XXIII.1 of the Securities Act to advance a secondary market misrepresentation claim against a lender to an insolvent issuer following the issuer's collapse.
Applying the Supreme Court's Theratechnologies screening standard, the court held that the plaintiff failed to provide both a plausible interpretation of the promoter provisions and sufficient evidence showing a reasonable possibility of success at trial.
The court found that conventional banking, financial advisory, underwriting, and lending activities, even if essential to the transaction, did not amount to taking the initiative in founding, organizing, or substantially reorganizing the issuer's business.
The court also found insufficient evidence that the defendant knowingly influenced the release of the impugned disclosure documents.
Leave was denied.